What happened
SK Bioscience filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$127M (+17.4% year on year), an operating loss of US$35.5M and a net loss of US$38.8M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$127M |
|---|---|
| Revenue vs a year earlier | +17.4% |
| Operating profit | −US$35.5M |
| Net income | −US$38.8M |
| Period | Q4 2025 (consolidated) |
| Filed | 2026-02-03, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260203800694 → open original filing |
Source: DART. Information only, not investment advice.